Etoposide

依托泊苷

Report date: 2026/04/24 20:01:59
NME

Base Information

Drug NameEtoposide
Drug Alias Name足叶乙甙etoposide鬼臼乙叉苷Etoposidum鬼臼乙叉甙 +[18] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTopoisomerase II inhibitors
TargetsTopoisomerase II
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Diffuse midline gliomaLymphohistiocytosis, Hemophagocytic +[11] 
Global Approved IndicationsUrinary Bladder NeoplasmsSmall Cell Lung CarcinomaTesticular Neoplasms +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved DateN/A
Country/TerritoryUnited StatesFranceEU +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCorden Pharma
China Registration ClassN/A

Develop Information

Active CompaniesHefei University Of TechnologyWuhu Changjiang Pharmaceutical Co LtdAssistance Publique Hopitaux De Paris +[7] 
Inactive CompaniesCorden Pharma Latina SpaBoston Medical Center Inc
Active IndicationsDiffuse midline gliomaLymphohistiocytosis, HemophagocyticUrinary Bladder Neoplasms +[10] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeL01CB01
Related LinksWikipediaDrugBankKEGG